The SLINGSHOT-1L (SSH1L) antibody targets SLINGSHOT homolog 1 (SSH1), a phosphatase critical for regulating actin cytoskeleton dynamics. SSH1 specifically dephosphorylates and activates cofilin, a protein that disassembles actin filaments, enabling cell motility, morphogenesis, and intracellular trafficking. Dysregulation of SSH1-cofilin signaling is implicated in cancer metastasis, neurological disorders, and immune cell dysfunction. The SLINGSHOT-1L antibody is designed to detect SSH1 isoforms, particularly the long variant (SSH1L), which contains unique regulatory domains absent in shorter isoforms. It is widely used in research to study SSH1 expression, localization, and activity in cellular models, employing techniques like Western blotting, immunofluorescence, and immunohistochemistry. By enabling precise tracking of SSH1 in physiological and pathological contexts, this antibody aids investigations into mechanisms underlying tumor invasion, neuronal plasticity, and inflammatory responses. Its specificity for SSH1L helps distinguish it from closely related family members (SSH2/3), minimizing cross-reactivity. Validated in multiple studies, the SLINGSHOT-1L antibody has become a key tool for unraveling cofilin-mediated actin remodeling pathways and their therapeutic targeting in diseases like cancer and Alzheimer’s.